SPAC merger with TCGX Acquisition Corp. announced with $160M PIPE, about $246M expected gross proceeds; Phase 3 migraine programme; no commercial or regulatory leader on leadership page
Chief Commercial Officer · Independent Board Director · General Counsel
Jeff Goater Chief Executive Officer, TriGemX Bio
01
Dren Bio
San Carlos CA ·
$350M private financing closed to fund late-stage development, filing and planned launch of dibotatug; two investor partners join board
CFOVP Sales
What happened
Dren Bio announced the closing of an oversubscribed $350 million private financing, 29 Oct 20261
Round co-led by Juvia Group and Lightspeed Venture Partners; new investors include Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management and OrbiMed1
Proceeds to support continued late-stage clinical development, regulatory submission and planned commercial launch of dibotatug (DR-01), and expansion into additional indications and the broader pipeline1
Sujal Shah (Co-Founder and Managing Director, Juvia Group) and Shelley Chu, M.D., Ph.D. (Partner, Lightspeed) appointed to the Board of Directors1
Dibotatug: Ph1/2 study in cytotoxic T-cell lymphoma and LGLL with more than 300 patients dosed; no filing date stated1
Leadership page lists a CEO, a President and COO, an EVP Finance, an SVP Head of Commercial, an EVP Head of Clinical Development, an SVP Regulatory Affairs and a VP Medical Affairs; it lists no Chief Financial Officer, Chief Medical Officer, Chief Commercial Officer or head of People (checked 31 Oct 2026)2
SVP Head of Commercial Benjamin Kozub joined in May 2026 and VP Medical Affairs Johnathan Maher in October 20262
The release states a planned commercial launch of dibotatug; it names no commercial partner, no search and no new executive1
BioSpace (29 Oct 2026): the Phase 1/2 trial of dibotatug in CTL and LGLL has a primary readout slated for this December, according to ClinicalTrials.gov3
BioSpace (29 Oct 2026): Dren lists the haematologic malignancy programme in its online pipeline as in registrational development3
Dren Bio closed a $350 million round on 29 Oct 2026 to fund the regulatory submission and planned commercial launch of dibotatug, and its leadership page shows finance led by an EVP Finance with no Chief Financial Officer listed, so a launch-stage CFO may be among the next senior hires12. The commercial build has started, with an SVP Head of Commercial who joined in May 2026 and a VP Medical Affairs who joined in October 2026, which suggests field leadership such as a VP Sales may follow as the launch nears2. BioSpace reported on 29 Oct 2026 that the CTL and LGLL trial has a primary readout slated for this December, which may be when filing and launch hiring firms up3.
What could hold it back
Shown EVP Finance Jeff Macfarland has been in post since May 2021, so the company could elevate him rather than search for a CFO2.
Shown The company has stated no filing date, and the trial readout is still ahead, so launch hiring may wait on the data13.
Open Whether a search firm is already engaged, or whether the new lead investors on the board bring candidates from their own networks.
About the decider: Nenad Tomasevic
Nenad Tomasevic co-founded Dren Bio as CEO in May 2019; before that he was VP of Research at Allakos, which he helped co-found. The $350 million round puts the regulatory submission and planned launch of dibotatug on his desk, alongside two new investor directors from Juvia Group and Lightspeed21.
Questions to ask Nenad Tomasevic
With the $350 million round funding the regulatory submission and planned launch of dibotatug, which leadership roles do you expect to add first as Dren Bio moves toward being a commercial company1?
Having built Dren Bio from research through late-stage development, how are you thinking about the finance function as the company prepares for a launch21?
With a Head of Commercial and a VP Medical Affairs now in post, how do you see the commercial team being built out around the trial's readout23?
Who to call
Decides
Nenad Tomasevic
Chief Executive Officer and Founder, Dren Bio
Verified
✓ drenbio.com, 31 Oct 2026
Domain
drenbio.com
Profile
LinkedIn not found
Co-founded Dren Bio as CEO in May 2019; previously VP of Research at Allakos, which he helped co-found2
Influences
Sujal Shah
Co-Founder and Managing Director, Juvia Group; new Dren Bio board member
Benjamin Kozub joins as SVP, Head of Commercial (from CymaBay)2
Expanded Sanofi collaboration on a B-cell depleting therapy: $100 million upfront, up to $1.7 billion in milestones; option to co-fund for US co-promotion rights6
Shalini Gidwani joins as SVP of Regulatory Affairs2
Senior Vice President and Head of Research Bret Williams leaves for Fathom Therapeutics as CSO; no successor, interim or search stated by Magnet
VP Research
What happened
Fathom Therapeutics announced on 29 Oct 2026 that Bret Williams, Ph.D., is its new Chief Scientific Officer; he joins from Magnet Biomedicine, where he most recently served as senior vice president and head of research1
The release gives no start date at Fathom and does not say when he left Magnet1
Magnet's own site (checked 31 Oct 2026) lists no Head of Research, SVP Research or VP Biology; its leadership list shows President & CEO, CMO, CBO and VPs of Drug Discovery, Operations, Portfolio & Program Management, Clinical Operations and Regulatory Affairs. It states no vacancy, interim or search2
On 14 Oct 2026 Magnet said Lilly had exercised its right to designate up to two additional collaboration projects, bringing the total to three active molecular glue programmes3
Magnet signed a collaboration and license agreement with Eli Lilly on 28 Feb 2025, to receive up to $40 million in upfront, near-term payments and an equity investment4
CEO Brian Safina said the Lilly deal helps fund work toward the clinic and that Magnet could raise more as programmes approach it; no timeline given5
Magnet's senior vice president and head of research, Bret Williams, has left to become Chief Scientific Officer at Fathom Therapeutics (announced 29 Oct 2026), and Magnet's leadership page, checked 31 Oct 2026, lists no research head and names no successor or interim12. On 14 Oct 2026 Magnet said Lilly had designated up to two more projects, bringing it to three active molecular glue programmes with Lilly, alongside its own ST2 and TL1A programmes at lead optimisation, so senior research leadership may be among its next hires32. The CEO has said the Lilly deal helps fund work to take programmes into the clinic, with a further raise possible as they approach it, a stage that often calls for a research leader able to hand candidates to development5.
What could hold it back
Shown Matthew Hayward, VP of Drug Discovery, is in post and could cover the research work2.
Open Whether Magnet has begun a search, named an interim, or will take a candidate from ARCH or Newpath's network.
About the decider: Brian Safina
Brian Safina is President & CEO of Magnet; before Magnet he was at Bolt Biotherapeutics and spent 2004 to 2018 at Genentech. The departure of the head of research may put the shape of research leadership on his desk while the Lilly collaboration grows to three programmes2613.
Questions to ask Brian Safina
How are you thinking about research leadership now that the Lilly collaboration has grown to three active programmes3?
As ST2 and TL1A move toward the clinic, which senior capabilities do you expect the team to need next25?
How do ARCH and Newpath usually take part when Magnet adds senior leaders7?
Who to call
Decides
Brian Safina
President & Chief Executive Officer, Magnet Biomedicine
President and Chief Scientific Officer, Magnet Biomedicine
Senior Vice President, Discovery Research, Bolt Biotherapeutics, Inc.
Vice President, Protein & Medicinal Chemistry, Bolt Biotherapeutics, Inc.
Vice President, Chemistry, Bolt Biotherapeutics, Inc.
The Scripps Research Institute, Organic Chemistry; University of California, San Diego, PhD, Synthetic Organic Chemistry; Loyola Marymount University, Bachelor's degree, Chemistry
Flagship Pioneering merges Cellarity, Etiome and Empress platforms into Etcelera; no leadership beyond CEO and chair named
Chief Business Officer
What happened
Flagship Pioneering announced the formation of Etcelera on 29 Oct 2026, created by the merger of the platforms of Cellarity, Etiome and Empress Therapeutics1
Ad Rawcliffe, CEO-Partner at Flagship Pioneering, leads Etcelera as CEO; the release names no other executives2
Alec Reynolds, Senior Partner at Flagship Pioneering, is Chairman of Etcelera2
No new funding was announced with the launch; the three predecessor companies had raised $374 million in venture capital before the merger3
CEO says the next six to 12 months will bring substantial business development activity with partners4
An oral sickle cell disease drug that Cellarity discovered moves into a separate standalone company, not Etcelera3
Etcelera keeps the 2022 Novo partnership with Cellarity in MASH; a second large-pharma alliance is in the works, per the CEO3
Company site shows a single line about the three companies and no leadership page (checked 31 Oct 2026)5
CEO Ad Rawcliffe describes Etcelera's future as quite partnership oriented4
The release states the company's goal includes high-impact partnerships and data services alongside more and better medicines1
Rawcliffe said the $374 million the three predecessors raised will help carry the company further3
Flagship formed Etcelera on 29 Oct 2026 from the platforms of Cellarity, Etiome and Empress Therapeutics, and the launch names only the CEO and the chair12. The CEO calls the company's future quite partnership oriented and says the next six to 12 months will bring substantial business development activity, with the Novo MASH partnership retained and a second large-pharma alliance in the works, so senior deal leadership may be among the first seats the combined company fills43.
What could hold it back
Open Whether business development leaders from Cellarity, Etiome or Empress carry over into Etcelera; no page names them.
Open Whether Flagship, which supplies the CEO and chair, places someone from its own network or runs the hire through its own talent team.
Shown No new funding was announced with the launch; the CEO says the $374 million the three companies raised will help carry the company further, so the pace of senior hiring may depend on existing capital3.
About the decider: Adrian (Ad) Rawcliffe
Ad Rawcliffe has been CEO of Etcelera since its formation on 29 Oct 2026 and CEO-Partner at Flagship since Jan 2026, when he also became CEO of Etiome; before that he was CEO of Adaptimmune (Aug 2019 to Jan 2026), its CFO from Mar 2015, and earlier SVP Worldwide Business Development at GlaxoSmithKline. The merger puts the combination of three platforms and a planned run of partnering deals over the next six to 12 months on his desk2647.
Questions to ask Adrian (Ad) Rawcliffe
Having led worldwide business development at GlaxoSmithKline, how are you thinking about the team that will carry the partnering activity you expect over the next six to 12 months47?
Now that the Cellarity, Etiome and Empress platforms sit in one company, which leadership roles do you see the combined company needing first1?
With partnerships and data services alongside your own hematology, metabolism and immunology programmes, how do you see the balance between partnering and advancing programmes in-house14?
$200 million private financing for preclinical programs, after Incyte bought subsidiary Vega; no seat stated
Chief Medical Officer
What happened
Star Therapeutics announced a $200 million private financing on 23 Oct 2026, co-led by OrbiMed and Janus Henderson Investors1
Proceeds are to advance its current preclinical programs into the clinic and expand the pipeline with additional programs1
The financing follows Incyte's July 2026 completed acquisition of Star subsidiary Vega Therapeutics, including lead programme latarcibart (VGA039), in a transaction valued at up to $2 billion1
Janus Henderson's Vish Sridharan is joining as a board observer for Star1
Leadership page lists four managers: CEO/Founder/Board Chair, CSO, CBO and CFO (one person), and SVP Head of HR; it lists no chief medical, clinical development, regulatory, CMC/technical or commercial leader (checked 31 Oct 2026)2
Star’s lead program latarcibart (VGA039), in Phase 3 development, was included in the Vega Therapeutics sale to Incyte; the release describes Star’s current programs as preclinical1
Star's 21 Apr 2026 release quoted Gary Patou, M.D., as Chief Medical Officer of Star Therapeutics, while the VGA039 pivotal Phase 3 was enrolling3
Star has raised $200 million to take its preclinical programmes into the clinic, but the clinical-stage drug it had in Phase 3 went to Incyte with Vega Therapeutics in July 2026, so the company may be rebuilding its clinical side from a preclinical start1. Star named Gary Patou as its Chief Medical Officer, yet the leadership page checked on 31 Oct 2026 lists no medical or clinical leader32. That suggests a medical leader for the new programmes may be among the first senior hires this round funds, with the timing likely tied to when the first programme nears the clinic, which no page states12.
What could hold it back
Open When the first preclinical programme is expected to enter the clinic: the release gives no date, so the hire could wait until a programme is close.
Open Whether a medical leader has already been engaged, as an employee, adviser or consultant, without appearing on the leadership page, or whether a search is already under way.
Open Whether the lead investors place a candidate from their own networks.
About the decider: Adam Rosenthal
Adam Rosenthal founded Star in 2018 and has been CEO since inception; he is also Board Chair, and earlier was Chief Business Officer at True North Therapeutics and co-founder and CEO of Electra Therapeutics, and his profile lists him as CEO and co-founder of Vega Therapeutics (2018–2026). After Incyte's acquisition of Vega, he now has $200 million to take Star's preclinical programmes into the clinic and add new ones241.
Questions to ask Adam Rosenthal
Having taken VGA039 from the Star platform into a pivotal Phase 3 before the Vega sale, how are you thinking about the medical and clinical leadership for the next programmes as they approach the clinic13?
Which of the current preclinical programmes do you expect to lead into the clinic first, and what will the team need around it at that point1?
With OrbiMed and Janus Henderson co-leading the round, how do you and the board expect to approach the senior hires for this next phase1?
Who to call
Decides
Adam Rosenthal
Founder, Chief Executive Officer and Board Chair, Star Therapeutics
Founded Star in 2018 and has been CEO since inception; earlier Chief Business Officer at True North Therapeutics and co-founder and CEO of Electra Therapeutics2
Massachusetts Institute of Technology / Harvard Medical School, PhD, Biomedical Engineering; Massachusetts Institute of Technology, MEng, Electrical Engineering & Computer Science; Massachusetts Institute of Technology, BS, Electrical Engineering; Brain and Cognitive Science
Runs the process
Monica Kamio
SVP, Head of Human Resources, Star Therapeutics
Verified
✓ star-therapeutics.com, 31 Oct 2026
Domain
star-therapeutics.com
Profile
LinkedIn not found
Oversees HR strategy and operations including recruitment; earlier VP of Human Resources at Arch Capital Services2
Co-led by OrbiMed and Janus Henderson Investors, with Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Venture Partners, NYBC Ventures, RA Capital Management, Redmile, Sofinnova Investments, Soleus Capital and a leading sovereign wealth fund1
Type
Biotechnology company; current programmes preclinical1
Latest financing
$200 million private financing, 23 Oct 2026, co-led by OrbiMed and Janus Henderson Investors1
Address
201 Haskins Way, 5th Floor, South San Francisco, CA 940802
$62 million Series C closed to take HEX-360 into the clinic (first-in-human planned H1 2027); no seat stated
VP Clinical OperationsVP Regulatory Affairs
What happened
Hexagon Bio announced the closing of a $62 million Series C financing on 23 Oct 2026, led by The Column Group, with existing investors Nextech Invest, Deviation Capital, 8VC and CPP Investments participating1
The company says proceeds will support the Phase 1 trial of HEX-360 (expected to begin in the first half of 2027) and advance additional novel payload mechanisms and dual payloads from its ADC platform1
HEX-360 is currently in IND-enabling studies; the CEO says the capital lets the company transition into a clinical-stage company1
The release names no new executive, board member or search; it quotes CEO Maureen Hillenmeyer and Board Chairman Scott Garland1
The company's leadership page lists a CEO, Chief Scientific Officer, Chief Medical Officer (Bill Grossman), SVP Drug Discovery, SVP Business Development and two VPs (Biology; Synthetic Biology); it lists no CFO, no regulatory, clinical operations, CMC or people leader (checked 31 Oct 2026)2
Bill Grossman's own enGene page says he took the interim Chief Medical Officer role there in June 2026 while staying on enGene's board; Hexagon's page still lists him as Chief Medical Officer and states no change3
A Clinical Advisory Board of breast cancer experts was formed in June 2026 to support HEX-360 development4
A Hexagon Bio job posting dated 4 Sep 2026 seeks a Sr./Ex. Director or VP, Clinical Scientist, reporting to the Head of Clinical/CMO, to support clinical trial design and regulatory submissions including INDs5
Hexagon Bio closed a $62 million Series C on 23 Oct 2026 to fund the Phase 1 trial of HEX-360, now in IND-enabling studies and planned to begin in the first half of 2027, and its CEO says the money lets it transition into a clinical-stage company1. Its leadership page is built around discovery and business development, with a Chief Medical Officer but no clinical operations or regulatory leader, and a September 2026 posting for a clinical scientist reporting to the Head of Clinical/CMO suggests the clinical team is being built now, so the leaders who run a first IND and first trial may be among the next senior hires25.
What could hold it back
Shown A Chief Medical Officer, Bill Grossman, is listed on the leadership page and could carry clinical and regulatory leadership himself; his own enGene page says he also took an interim CMO role there in June 202623.
Open Whether The Column Group's talent team is already recruiting for these seats, or whether a CRO will run the Phase 1 with a lean in-house team.
Open Whether clinical operations or regulatory leads have already been hired below the level the leadership page shows.
About the decider: Maureen Hillenmeyer
Maureen Hillenmeyer co-founded Hexagon Bio and has been its CEO, coming from Stanford, where she directed the Genomes to Natural Products program. The Series C now puts on her desk the move from a discovery platform to a clinical-stage company, with HEX-360's Phase 1 planned for the first half of 202712.
Questions to ask Maureen Hillenmeyer
You have said the Series C lets Hexagon move quickly into being a clinical-stage company; how are you thinking about the leadership the HEX-360 Phase 1 will need around the start planned for the first half of 20271?
As the clinical team forms under the Chief Medical Officer, which parts of clinical operations and regulatory work do you expect to build in-house, and which to run with partners25?
With the round also funding further payload mechanisms and dual payloads, how do you see the balance of the leadership team shifting between the platform and development over the next year or two1?
Who to call
Decides
Maureen Hillenmeyer
Co-founder and Chief Executive Officer, Hexagon Bio
Director of Genomes to Natural Products Program, Stanford University School of Medicine
Group leader, Stanford University School of Medicine
Stanford University School of Medicine, Postdoctoral scholar, Biochemistry; Stanford University, PhD, Biomedical informatics; University of Notre Dame, BS, Biological Sciences
Runs the process
Carla Daniel
Partner & Chief People Officer, The Column Group (lead investor)
Joined The Column Group in 2015 and assists portfolio companies in recruiting their scientific teams; earlier in HR at Tularik, then roles at Genentech and an executive search firm6
University of California, Santa Cruz, Bachelor of Arts (BA), Anthropology; University of California, Santa Cruz, Master of Arts (MA), Molecular, Cellular and Developmental Biology
Influences
Leon Chen
Partner, The Column Group; listed on Hexagon Bio's board page
Stanford University Graduate School of Business, MBA, Business; Stanford University School of Medicine, PhD, Pharmacology; Stanford University, Ph.D, Molecular Pharmacology
First patient dosed in US Phase 3 AURORA trial of denifanstat in acne; no commercial or regulatory leader named on the leadership page
Chief Commercial OfficerVP Regulatory Affairs
What happened
First patient dosed in AURORA, Sagimet's pivotal US Phase 3 trial of denifanstat in moderate to severe acne, 22 Oct 2026; intended to support a potential US NDA1
Trial to enroll about 800 US patients, 450 of them adolescents; topline results expected in the second half of 20271
Sagimet develops denifanstat outside China; license partner Ascletis holds the exclusive China licence1
Sagimet closed an underwritten offering of about $115.0 million gross on 1 Oct 2026, led by Commodore Capital; proceeds to fund the Phase 3 trial, pre-launch activities for denifanstat and other programmes2
Sagimet intends to use the net proceeds of the Oct 2026 offering, with existing cash, to fund the Phase 3 trial of denifanstat in acne, pre-launch activities for denifanstat, TVB-3567 through Phase 2 topline results and its topical FASN inhibitor programme to IND2
Leadership page lists a Senior Vice President of New Products (Robert D'Urso, joined Sep 2024, formerly US Country Manager at ISDIN) and no Chief Commercial Officer, regulatory leader or head of manufacturing/CMC (checked 31 Oct 2026)3
Chief Medical Officer Andreas Grauer joined in April 20263
Sagimet dosed the first patient in AURORA, its pivotal US Phase 3 trial of denifanstat in acne, on 22 Oct 2026, with topline results expected in the second half of 2027 and the trial intended to support a potential US NDA1. Sagimet develops denifanstat outside China, and it raised about $115.0 million on 1 Oct 2026 partly to fund pre-launch activities for denifanstat, while its leadership page names no Chief Commercial Officer or regulatory leader123. That suggests commercial and regulatory leadership may be among the next senior hires as the company moves towards the 2027 readout and a potential filing after it12.
What could hold it back
Shown A Senior Vice President of New Products, Robert D'Urso, in post since Sep 2024 and formerly US Country Manager at ISDIN, could lead the commercial build3.
Shown Topline results are not expected until the second half of 2027, so commercial hiring may wait for the data1.
Open Whether Sagimet will launch in the US itself or seek a partner, and whether a commercial search is already under way.
About the decider: David Happel
David Happel has been CEO of Sagimet since Oct 2022, coming from the CEO roles at Cognoa and Chrono Therapeutics, with earlier commercial positions at Raptor Pharmaceuticals and Horizon. The AURORA start and the Oct 2026 financing for pre-launch work may put the shape of the company's first launch team on his desk32.
Questions to ask David Happel
How are you thinking about the commercial organisation denifanstat would need, and when it should start to take shape relative to the 2027 readout1?
The October financing is earmarked partly for pre-launch activities; which capabilities does the team see as the first priorities for that work2?
As AURORA heads towards a potential NDA, how do you see regulatory leadership developing alongside the clinical team1?
Joined as CEO in Oct 2022; previously President and CEO of Cognoa and CEO of Chrono Therapeutics; earlier roles at Horizon Therapeutics, Raptor Pharmaceuticals, Dynavax and Chiron3
General Counsel & Chief Compliance Officer from April 2023 to October 2025, then Chief Legal & Administrative Officer; previously General Counsel at Cognoa and Basilea3
Oct 2026 offering led by Commodore Capital, with RA Capital Management, Spruce Street Capital, BVF Partners, Aberdeen Investments, Columbia Threadneedle Investments, Affinity Asset Advisors and Woodline Partners2
Type
Clinical-stage biotech (lead programme denifanstat in Phase 3, acne)1
Latest financing
Underwritten offering of Series A common stock and pre-funded warrants, about $115.0 million gross, closed 1 Oct 2026 (8,750,010 shares at $10.00; pre-funded warrants for 2,750,010 shares)2
Cash and runway
Cash, cash equivalents and marketable securities of $257.6 million at 30 Jun 2026 (before the Oct 2026 offering); company states current operations funded through 202845
Address
950 Tower Lane, Suite 1500, Foster City, CA 944046
CEO succession plan: President Robin Swartz expected to succeed CEO Al Sandrock in Q1 2027; no CFO named since May 2026
Chief Executive Officer: filledCFOCOO
What happened
Board appointed Robin Swartz, Chief Business Officer and Chief Operating Officer, as President effective 20 Oct 2026; she is expected to succeed CEO Alfred Sandrock in Q1 2027, after initial acute safety data from the VY1706 trial12
Sandrock is expected to remain CEO through initial acute safety data with VY1706 (Q1 2027, pending enrollment) and then stay on the Board32
Chairman Michael Higgins said the Board unanimously selected Swartz; no search or search firm is mentioned in the release2
Swartz has led multiple functions at Voyager, including clinical development, finance, legal and HR2
Swartz has also been principal financial officer and treasurer since May 2026; the former CFO resigned effective 8 May 2026 and no new CFO is named45
Amy Quinlan, Vice President of Finance since January 2025, was appointed principal accounting officer on 20 Apr 2026, effective 8 May 20265
Leadership page lists its management team (CEO, President, Chief Scientific Officer, Chief Corporate Affairs Officer and Chief of Staff); it lists no CFO, COO, CBO, medical, regulatory or people leader (checked 31 Oct 2026)4
Seat in play
Chief Executive Officer: Filled (Robin Swartz named President and expected successor in Q1 2027; Sandrock remains CEO until then)1
Robin Swartz, Chief Business Officer and Chief Operating Officer and also principal financial officer and treasurer since the CFO left in May 2026, is expected to become CEO in Q1 2027 after initial acute safety data from VY1706, so the operating and finance seats she has carried may need holders around that handover15. The leadership page lists no CFO, and the Nasdaq-listed company reported $149 million in cash at the end of Q2 2026 with runway into 2028, so a dedicated finance leader may be among the first seats the incoming CEO looks at43.
What could hold it back
Shown VP Finance Amy Quinlan has been principal accounting officer since May 2026 and could take on more of the finance role5.
Shown The handover is tied to initial VY1706 safety data expected in Q1 2027 pending enrollment, so the timing could move, and Swartz has run finance without a CFO since May 2026, so the seats could stay absorbed24.
Open Whether a CFO or COO search is already under way, or a firm engaged.
About the decider: Robin Swartz
Robin Swartz was appointed President on 20 Oct 2026 and is expected to succeed Al Sandrock as CEO in Q1 2027; she joined Voyager in January 2021 and has been COO since February 2022, COO and CBO since November 2024, and principal financial officer and treasurer since May 2026. Before Voyager she spent 26 years at Genzyme and Sanofi Genzyme, including over ten years in finance, and the move may put her own former seats and the vacant CFO role on her desk14.
Questions to ask Robin Swartz
Having spent over ten years in finance at Sanofi Genzyme and served as Voyager's principal financial officer since May, how are you thinking about finance leadership as you move into the CEO role in Q1 20271?
With programmes advancing both in-house and with partners such as Alexion, Novartis and Neurocrine, how do you see the business and operating responsibilities you hold today being organised once you step up2?
As VY1706 approaches its initial acute safety data, what will the leadership team need for the next stage of development2?
Who to call
Decides
Robin Swartz
President, Voyager Therapeutics (expected CEO from Q1 2027)
Chief Operating Officer, Voyager Therapeutics, Inc.
SVP Portfolio Management and Patient Engagement, Voyager Therapeutics, Inc.
SVP, Head of Patient and Product Services, Sanofi Genzyme
VP, Global and US Business Operations, Sanofi Genzyme
Chief Of Staff, Office of the President , Sanofi Genzyme
Kenyon College, Bachelor's degree, Political Science and Government; IMD Business School, Executive Program; American University, Conflict Resolution and Policy
Decides
Alfred Sandrock
Chief Executive Officer, Voyager Therapeutics (expected to hand over the CEO role in Q1 2027)
Verified
✓ voyagertherapeutics.com, 31 Oct 2026
Domain
voyagertherapeutics.com
Profile
LinkedIn not found
Executive Vice President, Research and Development at Biogen from October 2019 to December 20214
Influences
Michael Higgins
Chairman of the Board, Voyager Therapeutics
Verified
✓ voyagertherapeutics.com, 31 Oct 2026
Domain
voyagertherapeutics.com
Profile
LinkedIn not found
Interim President and CEO of Voyager from June 2021 to March 20224
Positive Phase 2 bipolar mania data, then stock and convertible notes offerings closed; leadership page lists no commercial leader
Chief Commercial Officer
What happened
Positive topline results from the Phase 2 trial of RAP-219 in adults with acute bipolar mania, 20 Oct 2026; the trial met its primary endpoint1
Company plans an FDA meeting in Q1 2027 on registrational trial design; two Phase 3 trials in bipolar mania are expected to start in H2 20271
Phase 3 focal onset seizure trials FOCUS 1 and FOCUS 2 are already enrolling1
Underwritten common stock offering (net proceeds approximately $215.7 million) and $172.5 million convertible notes offering both closed 30 Oct 2026, with a concurrent private placement of about $30.0 million; proceeds are for RAP-219 clinical trials, other R&D and general corporate purposes23
Leadership page lists a CEO, CSO, COO, CFO, CMO, Chief Development Officer and Chief People Officer; it lists no commercial, business, regulatory or medical affairs leader (checked 31 Oct 2026)4
Greater China rights to RAP-219 are licensed to Tenacia Biotechnology (March 2026); Rapport keeps rights in all other territories5
Annual report states the company has exclusive global rights to commercialize its product candidates and will consider partnerships opportunistically6
In Aug 2026 the company stated it plans an End-of-Phase 2 meeting with the FDA to align on the design of a potential Phase 3 programme to support a New Drug Application for bipolar mania7
RAP-219 now has two pivotal Phase 3 trials enrolling in focal onset seizures and, after positive Phase 2 bipolar mania data on 20 Oct 2026, an FDA meeting planned for Q1 2027 and two bipolar Phase 3 trials expected in H2 2027, with the company describing a potential Phase 3 programme to support a New Drug Application17. Rapport keeps RAP-219 rights everywhere outside Greater China, closed about $215.7 million of stock and $172.5 million of convertible notes on 30 Oct 2026, and its leadership page lists no commercial leader, so a commercial head to prepare a possible first launch across two indications may be among its next senior hires524. Companies preparing a first launch often put commercial leadership in place ahead of filing.
What could hold it back
Shown The CEO was previously Head of Commercial at Keryx and VP Marketing at Ironwood, and the COO's background covers marketing, sales and launch strategy, including the LINZESS launch; commercial planning may sit with them for now4.
Shown The October proceeds are stated for RAP-219 clinical trials, other R&D and general corporate purposes, not a commercial build, and the annual report says partnerships will be considered opportunistically26.
Open Whether the company will launch RAP-219 in the US itself or with a partner, whether commercial leaders already sit below the executive team, and when the focal onset seizure Phase 3 reads out (no date found).
About the decider: Abraham N. Ceesay
Abraham N. Ceesay is CEO of Rapport; before that he was President of Cerevel Therapeutics (May 2021 to Feb 2023), CEO of Tiburio Therapeutics, COO at scPharmaceuticals, Head of Commercial at Keryx and VP Marketing at Ironwood. The bipolar data and the October financing likely put the shape of the late-stage and pre-launch team for RAP-219 on his desk41.
Questions to ask Abraham N. Ceesay
With the FDA meeting planned for Q1 2027 and bipolar Phase 3 trials expected in H2 2027 alongside FOCUS 1 and FOCUS 2, how are you thinking about the leadership the company will need as RAP-219 moves toward a New Drug Application17?
Having led commercial work at Keryx and marketing at Ironwood, how do you see commercial preparation for RAP-219 across epilepsy and bipolar mania, and when should it begin4?
With Rapport keeping rights outside Greater China, how is the team weighing building its own US commercial organisation against partnering56?
Who to call
Decides
Abraham N. Ceesay
Chief Executive Officer, Rapport Therapeutics
Verified
✓ rapportrx.com, 31 Oct 2026
Domain
rapportrx.com
Profile
LinkedIn not found
President of Cerevel Therapeutics from May 2021 through February 20234
Common stock offering (net proceeds approximately $215.7 million) and $172.5 million convertible notes, closed 30 Oct 2026; concurrent private placement of about $30.0 million2
Cash and runway
$436.1 million in cash, cash equivalents and short-term investments at 30 Jun 2026, excluding restricted cash, expected to fund operations into the second half of 2029 (before the October offerings)1
SPAC merger with TCGX Acquisition Corp. announced with $160M PIPE, about $246M expected gross proceeds; Phase 3 migraine programme; no commercial or regulatory leader on leadership page
TriGemX Bio and TCGX Acquisition Corp. (Nasdaq: TCGX) announced a definitive business combination agreement on 19 Oct 2026; the combined company will be TriGemX Bio, Inc. and is expected to trade on Nasdaq as TGEM1
Expected gross proceeds are about $246 million: about $86 million in TCGX's trust account (assuming no redemptions) and a concurrent $160 million PIPE at $10.00 per share from investors including TCGX, Viking Global Investors, ADAR1 Capital Management, BVF Partners, Samsara BioCapital and Vianti Capital1
The proceeds are to fund completion of the Phase 3 trials and an NDA submission for acute migraine, a migraine prevention trial, and key commercial readiness activities for a potential U.S. launch1
CEO Jeff Goater said the proceeds will fully fund Phase 3 development of elismetrep and key commercial readiness activities as the company prepares for a potential U.S. launch1
Closing is expected in the first quarter of 2027, subject to shareholder approvals and customary conditions; results from the first Phase 3 trial are anticipated in mid-20271
Existing TriGemX shareholders roll 100% of their equity; post-transaction equity value about $600 million assuming no redemptions1
Leadership page (checked 31 Oct 2026) lists CEO, President & Chief Medical Officer, CFO, VP Head of HR and FP&A, and VP Corporate Controller; it lists no commercial, regulatory, clinical operations, CMC, legal, investor relations or medical affairs leader2
Two pivotal Phase 3 studies and a long-term safety study of elismetrep are underway3
After closing, the New TriGemX board will initially have seven directors: six TriGemX designees, at least three of them independent under Nasdaq rules, and one TCGX designee, with a majority independent4
TriGemX's obligation to close is conditional on Available Closing Cash of at least $150,000,000; either party may terminate, subject to limited exceptions, if the deal has not closed by 30 Jun 20274
On 1 Oct 2026 the company relaunched as TriGemX with Jeff Goater appointed CEO and Aninda Katragadda CFO; Goater joined from The Column Group, where he continues as a Venture Partner, and previously was CEO of Surface Oncology and CFO of Voyager Therapeutics5
Cariad Chester, Managing Partner at TCGX, joined the TriGemX board as part of the $94M financing5
Doug Pagán, CFO of Kailera Therapeutics, was appointed to the TriGemX board on 5 Oct 20266
TriGemX says the about $246 million from its planned Nasdaq listing, expected to close in the first quarter of 2027, is to fund completion of Phase 3, an NDA submission for acute migraine and commercial readiness for a potential U.S. launch, yet its leadership page lists no commercial or legal leader12. The merger agreement sets a seven-person board after closing with a majority independent under Nasdaq rules, so board composition is likely to be worked on ahead of the listing4. With first Phase 3 results expected in mid-2027, a company preparing a first U.S. launch usually puts commercial leadership in place well ahead of approval, so these seats may form before the readout rather than after it1.
What could hold it back
Shown The closing is subject to shareholder approval and at least $150 million of available closing cash, and proceeds could be lower with redemptions; the agreement can be ended if the deal has not closed by 30 Jun 20274.
Shown The board already lists Doug Pagán, appointed on 5 Oct 2026, so the post-closing board may be drawn largely from current directors26.
Open Whether commercial hiring waits for the mid-2027 Phase 3 results, and whether The Column Group or TCGX will place executives from their own networks.
About the decider: Jeff Goater
Jeff Goater has been CEO since the company's relaunch as TriGemX on 1 Oct 2026, joining from The Column Group (still a Venture Partner) after serving as CEO of Surface Oncology and CFO of Voyager Therapeutics; his LinkedIn profile shows him a Partner at The Column Group from Jan 2024 to Sep 202657.
Questions to ask Jeff Goater
How are you thinking about the leadership team TriGemX needs in place by the time it lists on Nasdaq1?
The proceeds are earmarked for commercial readiness ahead of a potential U.S. launch: how do you see the commercial organisation taking shape around the mid-2027 Phase 3 results1?
With a seven-person, majority-independent board planned after closing, what experience is the board looking to add as the company becomes public4?
University of Rochester - Simon Business School, MBA; University of Rochester School of Medicine and Dentistry, MS, Microbiology / Immunology; University of Rochester School of Medicine and Dentistry, MS, Pathology
CEO Jay Luly to retire by 1 Feb 2027; board search under way, internal and external candidates, no successor named; new COO role created
President and Chief Executive Officer: Open from 2027-02-01 · Chief Financial Officer: Open · VP Regulatory Affairs: Probable
Bruce L. A. Carter Chairman of the Board, Enanta Pharmaceuticals
Open roles
10
Cardiff Oncology, Inc. (CRDF)
San Diego CA ·
Chief Medical Officer departed; interim CMO on a consulting agreement to 22 Apr 2027; Phase 3 planned Q1 2027
Chief Medical Officer: open
What happened
Roger Sidhu, MD, separated as Chief Medical Officer on 22 Oct 2026 in a mutually agreed transition (8-K filed 27 Oct 2026)1
Leila Alland, MD, named interim Chief Medical Officer, announced 27 Oct 2026; she succeeds Dr. Sidhu2
Dr. Alland serves under an amended and restated consulting agreement from 23 Oct 2026 until the earlier of 22 Apr 2027 or completion of services, extendable by mutual agreement; $35,000 a month for up to 50% of her professional time1
Neither the release nor the 8-K names a permanent successor, a search or a search firm, and neither states that Dr. Alland is a candidate for the permanent role21
The company plans to start its registrational Phase 3 study in first-line RAS-mutated metastatic colorectal cancer in Q1 20272
Phase 3 start is subject to securing additional financing, per the Q2 2026 results release (11 Aug 2026)3
Management page lists President & CEO, COO, CFO, Chief Accounting Officer and CSO plus the interim CMO; no head of people, regulatory, commercial or VP clinical development is listed (checked 31 Oct 2026)4
The registrational Phase 3 (CRDF-005) is designed as a global randomized controlled trial expected to enrol about 640 patients across sites in the US, Europe and other regions5
On 14 Sep 2026 Cardiff and Nerviano entered a settlement resolving the litigation and amended the onvansertib licence; the amendment gives Nerviano a board observer seat and a Scientific Advisory Board seat6
At a September 2026 investor conference, management said it is exploring possible regional partnerships and other collaborations to fund the Phase 37
Seat in play
Chief Medical Officer: Open (held on an interim basis by Leila Alland, MD, under a consulting agreement to 22 Apr 2027; no search or firm named)1
Our read
Cardiff's CMO separated on 22 Oct 2026 and the seat is held by an interim on a part-time consulting agreement that runs to 22 Apr 2027, with no successor, search or candidate named, so the choice of a permanent CMO appears to be still ahead12. The company plans to start a registrational, global Phase 3 of onvansertib in first-line RAS-mutated metastatic colorectal cancer in Q1 2027, enrolling about 640 patients across the US, Europe and other regions, which suggests the permanent holder may need late-stage oncology trial and regulatory experience25. The licence dispute with Nerviano over onvansertib was settled on 14 Sep 2026, and the CEO and CFO seats were filled in April 202668.
What could hold it back
Shown The Phase 3 start is subject to securing additional financing; cash of $34.5 million at 30 Jun 2026 is stated to last into Q3 2027, and the 10-Q states substantial doubt about the company continuing as a going concern35.
Shown The COO, Ajay Aggarwal, was previously SVP and Head of Clinical Development at Aclaris and CMO of CereXis, and could cover part of the clinical work; the interim's agreement can also be extended by mutual agreement41.
Open Whether Dr. Alland is a candidate for the permanent role, and whether a search or firm is already engaged.
What filling it could set off (our read)
Dr. Alland is an outside consultant, so confirming her may leave no seat behind at Cardiff. An outside appointee may leave a seat at their previous employer, unknown until named, and a new CMO preparing a roughly 640-patient global Phase 3 may often add clinical development leadership (the management page lists no VP Clinical Development)154.
About the decider: Mani Mohindru, PhD
Mani Mohindru, PhD, has been President and CEO of Cardiff Oncology since late March 2026 after serving as interim CEO from January 2026, and has been a director since 2021; she was earlier CEO of Novasenta and CereXis and CFO and Chief Strategy Officer of Cara Therapeutics. With the CMO separated and an interim in place to April 2027, she is likely to decide on a permanent CMO while preparing a Q1 2027 Phase 3 start that depends on new financing43.
Questions to ask Mani Mohindru, PhD
With the registrational Phase 3 in first-line RAS-mutated colorectal cancer planned for Q1 2027, what profile are you looking for in the medical leader who takes it through enrolment and readout2?
Having built a new executive team this year, with a CFO and a COO who has led clinical development, how do you see the medical and clinical roles dividing as the trial runs across the US and Europe845?
Dr. Alland's agreement runs to April 2027; how are you thinking about the timing of a permanent CMO relative to the Phase 3 financing and start1?
Who to call
Decides
Mani Mohindru, PhD
President and Chief Executive Officer, Cardiff Oncology
Interim CEO from January 2026, President and CEO from late March 2026, director since 2021; previously CEO of Novasenta and CereXis, and CFO and Chief Strategy Officer of Cara Therapeutics4
Influences
Ajay Aggarwal, MD, MBA
Chief Operating Officer, Cardiff Oncology
Verified
✓ cardiffoncology.com, 31 Oct 2026
Domain
cardiffoncology.com
Profile
LinkedIn not found
Joined April 2026; previously SVP and Head of Clinical Development at Aclaris Therapeutics and Chief Medical Officer of CereXis4
Clinical-stage biotech; lead onvansertib in a Phase 2 trial, registrational Phase 3 planned Q1 20272
Latest financing
Registered direct offering of common stock and warrants, about $10.1 million gross proceeds, completed 14 Jul 20265
Cash and runway
$34.5 million in cash, cash equivalents and short-term investments at 30 Jun 2026 (before the July offering); company states cash is sufficient to fund operations into the third quarter of 2027; 10-Q states substantial doubt about ability to continue as a going concern5
Settlement with licensor Nerviano Medical Sciences amending the 2017 licence for onvansertib, resolving litigation10
Q2 2026 results: $34.5 million cash and investments at 30 Jun, runway into Q3 2027; Phase 3 start Q1 2027 subject to financing3
About $10.1 million registered direct offering completed5
Cardiff sued licensor Nerviano Medical Sciences, which had alleged material breach in Feb 2026 and purported to terminate the licence3
Mani Mohindru named President and CEO; Josh Muntner appointed CFO (effective 6 Apr) and Ajay Aggarwal COO (effective 27 Apr)8
CEO Mark Erlander and CFO James Levine stepped down as part of a strategic leadership review; Mohindru named interim CEO; Brigitte Lindsay promoted to Chief Accounting Officer; search for permanent CEO and CFO started11
CEO Jay Luly to retire by 1 Feb 2027; board search under way, internal and external candidates, no successor named; new COO role created
President and Chief Executive Officer: open from 2027-02-01Chief Financial Officer: openVP Regulatory Affairs: probable
What happened
Enanta announced on 28 Oct 2026 that Jay R. Luly, Ph.D., age 70, will retire as President and Chief Executive Officer by 1 Feb 2027 after 23 years, and will serve as Strategic Advisor for the remainder of 20271
The Board of Directors has initiated a search for Dr. Luly's successor, considering both internal and external candidates; no successor, interim or search firm is named in the release1
Tara L. Kieffer, Ph.D., previously Chief Product Strategy Officer, was appointed to the newly created role of Chief Operating Officer; the release does not say she is a candidate for CEO1
Harry R. Trout III, Vice President, Finance, was designated interim principal financial officer by the board on 26 Aug 2025, in place of the Chief Financial and Administrative Officer; he signed the 10-Q of 12 Aug 2026 as Principal Financial Officer. No permanent Chief Financial Officer is named on a page opened23
The management team page lists the CEO, COO, Chief Legal Officer, Chief Business Officer, Chief Scientific Officer and Chief Medical Officer; it lists no Chief Financial Officer, head of people, commercial or regulatory leader (checked 31 Oct 2026)4
Enanta decided to lay off 37 employees, right-sizing across all departments, according to Fierce Biotech (29 Sep 2026)5
Lead programme zelicapavir (RSV): Enanta announced on 26 Oct 2026 that the first patient was dosed in the global Phase 2b/3 RESOLVE trial; topline Phase 2b data expected in 20276
Cash, cash equivalents and marketable securities were $211.5 million at 30 Jun 2026; the company states its funds, with retained HCV royalties, last into fiscal 20293
The Phase 2b portion of RESOLVE will include at least 200 patients and is designed to confirm the treatment effect size; the Phase 3 portion is expected to enroll about 660 patients6
The CEO retirement release lists among its risk factors Enanta's lack of clinical development experience and its ability to partner its RSV or other programs1
Seat in play
President and Chief Executive Officer: Open from 2027-02-01 (Dr. Luly retires "by February 1, 2027" (date may be earlier); board search under way, internal and external; no successor named)1
Chief Financial Officer: Open (duties held by Harry R. Trout III, Vice President, Finance, designated interim principal financial officer on 26 Aug 2025; no permanent CFO named on a page opened)23
The board has begun a search for a successor to CEO Jay Luly, who plans to retire by 1 Feb 2027, and is considering external as well as internal candidates, so the choice of a permanent leader is likely still ahead1. The finance seat has been covered on an interim basis by VP Finance Harry Trout since Aug 2025 and the management team page lists no CFO234. The next CEO would take over as the lead RSV programme zelicapavir enters a Phase 2b/3 trial, with Phase 2b data expected in 2027 and funding stated to last into fiscal 2029, which may shape the profile the board looks for63.
What could hold it back
Shown The board is considering internal candidates, and Tara Kieffer was named to the newly created COO role on the same day, a natural successor seat for CEO1.
Open Whether a search firm is already engaged for the CEO search the board began on 28 Oct 2026.
Shown The Phase 3 portion of RESOLVE follows Phase 2b data expected in 2027, and the company decided to lay off 37 employees, as reported in Sep 2026, so a regulatory hire may wait for the data or be covered by the existing clinical team65.
What filling it could set off (our read)
If the board appoints from within, the seat that person holds now, such as Chief Operating Officer (Tara Kieffer) or Chief Business Officer (Brendan Luu), may open. A new CEO often reshapes the seats reporting to them in the first year, and may look to fill the CFO seat that a VP Finance has covered on an interim basis since Aug 2025142.
About the decider: Bruce L. A. Carter
Bruce Carter has chaired Enanta's board since Dec 2015 (director since Nov 2013) and was President and CEO of ZymoGenetics from 1998 to 2009 and Chief Scientific Officer of Novo Nordisk from 1994 to 1999. The board he chairs has opened the search for Jay Luly's successor, with internal and external candidates, ahead of a retirement dated by 1 Feb 202771.
Questions to ask Bruce L. A. Carter
Having led ZymoGenetics as CEO for over a decade, how is the board thinking about the experience Enanta's next chief executive will need as zelicapavir moves through RESOLVE toward Phase 2b data in 202776?
With Tara Kieffer now in the newly created COO role, how does the board see the senior team taking shape around the next CEO1?
How is the board thinking about finance leadership alongside the CEO transition34?
Who to call
Decides
Bruce L. A. Carter
Chairman of the Board, Enanta Pharmaceuticals
Verified
✓ businesswire.com, 28 Oct 2026
Domain
enanta.com
Profile
LinkedIn not found
Board member since Nov 2013 and Chairman since Dec 2015; former President and CEO of ZymoGenetics (1998 to 2009) and Chief Scientific Officer of Novo Nordisk (1994 to 1999)7
Joined Enanta in Dec 2020, most recently Chief Product Strategy Officer; previously Vice President of External Innovation and Business Development and Vice President of Integrated Program Management at Vertex Pharmaceuticals4
SVP, New Product Strategy and Development, Enanta Pharmaceuticals
VP, External Innovation, Business Development, Vertex Pharmaceuticals
VP, Integrated Program Management, Vertex Pharmaceuticals
The Johns Hopkins University School of Medicine, Doctor of Philosophy - PhD, Immunology; Colgate University, Bachelor of Arts - BA, Molecular Biology; Damascus High School
Clinical-stage biotech (lead programme zelicapavir, RSV, in Phase 2b/3); receives royalties on AbbVie's MAVYRET/MAVIRET6
Size
120 full-time employees at 30 Sep 2025 (annual report, as reported by Fierce Biotech); layoff of 37 reported 29 Sep 20265
Latest financing
Upsized public offering of common stock closed 2 Oct 2025: 7,475,000 shares at $10.00, gross proceeds $74.75 million8
Cash and runway
$211.5 million in cash, cash equivalents and marketable securities at 30 Jun 2026; funds, with retained HCV royalties, expected to last into fiscal 20293